Prostate cancer is the most common non-skin related cancer affecting 1 in 7 men in the United States. Treatment of patients with prostate cancer still remains a difficult decision-making process that requires physicians to balance clinical benefits, life expectancy, comorbidities, and treatment-related side effects. Gleason score (a sum of the primary and secondary Gleason patterns) solely based on morphological prostate glandular architecture has shown as one of the best predictors of prostate cancer outcome. Significant progress has been made on molecular subtyping prostate cancer delineated through the increasing use of gene sequencing. Prostate cancer patients with Gleason score of 7 show heterogeneity in recurrence and survival outcomes. Therefore, we propose to assess the correlation between histopathology images and genomic data with disease recurrence in prostate tumors with a Gleason 7 score to identify prognostic markers. In the study, we identify image biomarkers within tissue WSIs by modeling the spatial relationship from automatically created patches as a sequence within WSI by adopting a recurrence network model, namely long short-term memory (LSTM). Our preliminary results demonstrate that integrating image biomarkers from CNN with LSTM and genomic pathway scores, is more strongly correlated with patients recurrence of disease compared to standard clinical markers and engineered image texture features. The study further demonstrates that prostate cancer patients with Gleason score of 4+3 have a higher risk of disease progression and recurrence compared to prostate cancer patients with Gleason score of 3+4.
INTRODUCTION
Prostate cancer is the most common non-skin related cancer affecting 1 in 7 men in the United States.
1 In 2016, the estimated numbers of death from prostate cancer was 26,120 and new cases account for 21% of all newly cancer diagnoses in men each year. 1 Gleason grading is a strong predictor of survival among men with prostate cancer. Gleason score is a sum of the primary and secondary patterns with a range of 2 to 10. Studies show that patients with Gleason 4+3 tumors compared to Gleason 3+4 tumors had an increased risk of prostate cancer specific mortality and increased risk of recurrence and progression. [2] [3] [4] As such, these studies indicate that delineating prostate cancer patients with Gleason score 7 into 3+4 and 4+3 has a prognostic significance for patients disease management and survival.
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There have been many studies on computer-aided Gleason grading. [6] [7] [8] [9] [10] [11] [12] In general there are four approaches that have been used to assess prostate Gleason pattern grading including color-statistical based, 6, 9 texturebased, 8, 10, 13 structure-based 8, 14, 15 and tissue-component-based. [16] [17] [18] Gleason pattern 3 has a relative clear glandular shape while the Gleason pattern 4 consists of a range of various glandular patterns including glomeruloid glands, cribriform glands, poorly formed and fused glands and irregular cribriform glands. Convolutional Neural Networks (CNN) based histopathology image analyses have demonstrated significant advances in tissue and cellular segmentation [19] [20] [21] and classifications. [21] [22] [23] [24] Due to a large size of a WSI (typically a few GB/per WSI) that leads to not practicable for Gleason grading directly, we model the computational image biomarkers extracted from automatically cropped patches within the WSI to differentiate the images with different Gleason patterns. To further explore, the Microarray-based gene expression signatures have been used in various studies to identify cancer subtypes, determine the recurrence of disease and response to specific therapies. 25 Multiple studies have also shown that gene expression signatures can be used to analyze oncogenic pathways and these signatures have been used to identify differences between specific cancer types and tumor subtypes. Moreover, patterns of oncogenic pathway activity have been used to identify differences in underlying molecular mechanisms and shown to correlate with clinical outcome of specific cancers.
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In the study, we apply the prostate cancer patients disease free time (months) since their initial treatment as the time-to-recurrence as the time variable for Cox survival model. Using the survival model, we assess the image biomarkers and genetic biomarkers related to recurrence hazard risk scores for prostate cancer patients with Gleason score of 7 in the context of other clinical prognostic factors, including the primary and the secondary Gleason patterns, patients' prostate-specific antigen (PSA), age and clinical tumor stage by using our approach of neural networks analysis. The architecture of the neural networks is illustrated in Figure 1 
METHODS 2.1 Patch Sequence Modeling
In the study, we identify image biomarkers within tissue whole-slide images (WSIs) by modeling the spatial relationship of patches as a temporal sequence by adopting a recurrence network (RNN) model , 29 namely the long short-term memory (LSTM) 30 to learn the fine-grained discriminative information among patches (here Gleason patterns 3 and 4) and the global representation of the WSIs.
Pathway Score
We examine genomic-based patterns of oncogenic pathway activity, the tumor microenvironment and other important features in human prostate tumors using a panel of 270 previously published gene expression signatures. We apply each signature to the prostate cancer gene expression microarray data from the TCGA/GDC data portal, for which the Gleason subtype have been determined. Consistent patterns of pathway activity emerge for each subtype, and we quantitatively assesses these patterns using a Student's two tailed t-test, where a p-value of 0.01 or less is considered significant. To apply a given signature to a new data set, the expression data are filtered to contain only those genes that met the previous criteria, and the mean expression values are calculated using all genes within a given signature. The methods detailed in the original studies are followed as closely as possible.
27, 28
In conjunction with clinical prognostic features including the primary and secondary Gleason patterns, patients' prostate specific antigen (PSA), age and tumor stage, image biomarkers and pathway scores are fed into a Cox survival model for studying patients recurrence to advanced disease. 
EXPERIMENTS AND RESULTS
The tissue WSIs used in the study are from Cancer Genome Atlas (TCGA) and genetic data are from Genomic Data Commons (GDC). Patients with Gleason score 7 (3+4 and 4+4) are included in the study for the primary Gleason pattern 4 is a significant cut-off point for patients with prostate cancer, who wont be recommended active surveillance, but surgery instead. The image patches within each WSI are automatically cropped under 40X objective magnification with a patch size 4096x4096. No tissue, less tissue and low signal-to-noise ratio (SNR) patches are automatically eliminated from the experiments due to the heterogeneous quality of the GDC prostate WSIs. The patches with the tissue accounting for at least 20% of the whole area with high signal-to-noise ratio (SNR) are selected as the input of our experiments. This data preparation process keeps the integrity of tissue region meanwhile and has no discontinuity impact on LSTM. In total, 146 Gleason 3+4 and 101 Gleason 4+3 WSIs include 4753 and 2997 patches respectively. The patches inter-spatial relationship as an image sequence within a given WSI are modeled by CNN-based LSTM. The patches are warped to 256x256 and fed into the convolutional neural networks (CNN) with multi-task loss. Each patch is assigned two labels; one is the primary pattern and the other is the sum of the Gleason score. The momentum and weight decay of the CNN are 0.9 and 5x10 −5 respectively. The initial learning rate is 10 −3 and annealed by 0.1 after 100 iterations. The train the LSTM, we apply the same momentum, weight decay and initial learning rate. The CNN-LSTM implementation is based on Caffe toolbox. Table1 shows the hazard ratios of recurrence of the disease using different image features (LBP, HOG, SURF, neurons) with pathway scores. From the result, image biomarkers using CNN-LSTM outperforms other image feature quantification methods. With pathway score, image and genetic biomarkers show the highest recurrence hazard ratio compared to other clinical prognostic features. 
CONCLUSION
Our preliminary results demonstrate that integrating image features with genomic pathway scores, are more strongly correlated with patients recurrence of disease compared to standard clinical markers and engineered image texture features. The study further demonstrates that prostate cancer patients with Gleason score of 4+3 have higher risk of disease progression and recurrence compared to prostate cancer patients with Gleason score of 3+4. As such, we propose that patients with a Gleason score of 7 should not be considered as a homogeneous group for disease management and prognosis.
